Triple-Negative Breast Cancer Treatment
About Triple-Negative Breast Cancer (TNBC): Triple-negative breast cancer accounts for approximately 10 to 15% of all breast cancers. The term triple-negative breast cancer (TNBC) refers to the fact that the cancer cells don’t have estrogen receptors (ER) or progesterone receptors (PR) and also don’t create any or excess protein known as HER2. (The cells test "negative" on all 3 tests.) These cancers tend to be a bit more common in women aged less than 40, who are Black, or who have a BRCA1 mutation. Triple-Negative Breast Cancer differs from other kinds of invasive breast cancer in that it tends to progress and spread quickly, has limited treatment options, and tends to have a poor prognosis (outcome). Common Characteristics of Triple-Negative Breast Cancer: Triple-negative breast cancer (TNBC) is usually a bit more aggressive, difficult to treat, and more likely to recur than cancers that are HR-positive or HER2-positive. Who Gets Triple-Negative Breast Cancer: Triple-negative breast cancer (TNBC) is more common in: • women aged less than 40 • Black women